For example, MRX34 (ClinicalTrials.gov Identifier: NCT01829971), the first miRNA (miR-34a) mimic to reach a phase 1 clinical study for the treatment of primary liver cancer and other malignancies, was terminated due to the detection of five immune-related serious adverse events [273]. Here, IL1RAPL1 is linked to liver cancer.